HOLLISTON, Mass., June 19, 2017 /PRNewswire/ -- Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that it presented positive preclinical data of its proprietary Cellspan™ Esophageal Implant at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting held June 14-17, 2017 in Boston, MA.
Today the company has scheduled a meeting with Nasdaq to discuss their listing requirements & special circumstances. 6/22
There will not be a reverse split IMO because that does not change the minimum valuation requirement.
The only thing that works IMO is getting the share price up. If I remember correctly there are a bunch of warrants to be exercised @.50 cents which should help with that valuation.